Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price
Vanda Pharmaceuticals (VNDA) reported weaker Q2 results, with revenue down 18% to $51m versus analyst estimates. Statutory loss was $1.04 per share, 77% worse than expected. Four analysts cut the consensus 12-month price target 12% to $12.44 and lowered revenue forecasts, while 2026 revenue consensus is $253.5m.
How this was made
The 30-second read
Why it matters
Analysts downgraded revenue expectations and increased expected losses, while also lowering the consensus price target by 12%. This combination typically increases near-term risk premium even if longer-term growth assumptions remain intact.
Market read
Traders get a concrete post-earnings read-through: revenue miss, higher expected losses, and a lower consensus target, which can drive positioning into subsequent sessions.
What to watch
The piece is based on consensus/forecast aggregation rather than new primary disclosures; traders may want to verify the underlying drivers of the Q2 revenue miss and the assumptions behind the 2026 growth acceleration.
Background
The article frames Vanda’s recent Q2 results as disappointing and summarizes how analysts updated revenue, loss expectations, and the consensus price target after the report.
Ticker impact
Vanda reported Q2 results with revenues down 18% vs estimates and analysts cut the consensus price target 12% to $12.44.
Near-term downside bias as revised revenue and higher expected losses can pressure valuation multiples.
The article provides specific post-earnings forecast changes: revenue miss, higher expected losses, and a 12% reduction in the consensus target, which typically aligns with bearish repricing.
Market effects
Signals continued valuation pressure for specialty pharma names when revenue growth disappoints and losses widen.
No specific regional spillover described beyond US-listed biotech sentiment.
No direct global catalyst mentioned; impact appears company-specific.
Counterpoint
Despite the revenue downgrade, the article notes analysts still expect faster revenue growth into 2026, which could support a rebound if execution improves.
Key entities
- companyVanda Pharmaceuticals Inc.
US-listed specialty pharma issuer whose Q2 results and subsequent analyst forecast changes are summarized.
